|
 |
FrovatriptanThis page contains recent news articles, when available, and an overview of Frovatriptan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Frovatriptan (when available) Frovatriptan is a selective 5-hydroxy-tryptamine1 (5-HT1B/1D) receptor subtype agonist, indicated for the acute treatment of migraine attacks with or without aura in adults. Frovatriptan is a 5-HT receptor agonist that binds with high affinity for 5-HT1B and 5-HT1D receptors. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites. For treatment of acute migraine headache in adults Mechanism Of Action: Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Frovatriptan is a 5-HT receptor agonist that binds with high affinity for 5-HT1B and News Articles on Frovatriptan Frovatriptan Prevents Difficult-to-Treat Menstrual Migraine ... - Aug 25, 2008 By Sara Freeman GLASGOW, United Kingdom -- August 25, 2008 -- The ability of frovatriptan to prevent difficult-to-treat migraines is more than doubled if DG News Trattamento della cefalea primaria - Sep 11, 2008 I triptani in commercio sono: Almotriptan ( Almogran ), Frovatriptan ( Rilamig ), Naratriptan, Rizatriptan ( Maxalt ), Sumatriptan ( Imigran ), Zolmitriptan XagenaSalute, Recordati Reports Revenue and Earnings Growth in the First Half 2008 - Jul 30, 2008 Frovatriptan is a selective 5HT1B/1D receptor agonist. Frovatriptan is distinguished from other triptans by its long half- life (26 hours) which ensures MarketWatch ### Borsa: i titoli segnalati dall'esperto - Jul 9, 2008 ...apporti derivanti dalla commercializzazione del nuovo combo con enalapril e di nuovi farmaci tra i quali rupatadina, silodosin, Kentera e Frovatriptan. TGCOM, Kombitherapie - Option auch bei Migräne - Jul 14, 2008 In Deutschland für die orale Therapie erhältlich sind Almotriptan (Almogran®), Eletriptan (Relpax®), Frovatriptan (Allegro®), Naratriptan (Naramig®, Ärzte Zeitung, Vernalis concentrates on Cambridge following sale of US operations - Jun 5, 2008 ...frovatriptan, and in one stroke ended its ambition of becoming a sustainable, self-funding, R & D-driven, speciality pharmaceutical company. Business Weekly, REG-Vernalis PLC Interim Management Statement - Jun 5, 2008 In return, Vernalis made a cash payment to Endo of $7million and agreed to forego royalties from frovatriptan for US sales until they exceed $85million per PharmaLive.com (press release), Alternative Financing Strategies not a Cure-All for the Industry - Jun 19, 2008 Earlier this year, London-based Vernalis plc sold a share of its Frova (frovatriptan) revenues to Paul Capital Healthcare, while Cambridge, Mass. TMCnet Recordati SpA : RESULTATS POSITIFS POUR LE PREMIER TRIMESTRE 2008 ... - May 6, 2008 Frovatriptan is a selective 5HT1B/1D receptor agonist. Frovatriptan is distinguished from other triptans by its long half-life (26 hours) which ensures Le Revenu, Vernalis signs 18.4 million euros financing deal with Paul Capital ... - Apr 21, 2008 Vernalis will continue to supply Menarini with the frovatriptan active pharmaceutical ingredient. Earlier this year, the company announced a dramatic Hemscott, London close: Blue chips fall back - Apr 21, 2008 Drug group Vernalis is to get a cash injection of €18.4m from Paul Capital Healthcare in a financing agreement relating to frovatriptan, Vernalis' product ShareCast, Monday's company news - Apr 21, 2008 Drug group Vernalis is to get a cash injection of €18.4m from Paul Capital Healthcare in a financing agreement relating to frovatriptan, Vernalis' product Investors Chronicle, UK small caps stay higher at midday; Empyrean Energy top on ... - Apr 21, 2008 ...give Paul Capital 90 percent of the payments it would have received from European commercialisation partner Menarini for its frovatriptan migraine drug. Forbes, Endo Withdraws Frova Application - Apr 8, 2008 The sNDA was for the additional indication of Frova (frovatriptan succinate) for the short-term prevention of menstrual migraine. Endo said it is evaluating FDA news (subscription), Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC ... - Apr 7, 2008 ...new drug application (sNDA) without prejudice to refiling as afforded under 21 CFR 314.65 for FROVA® (frovatriptan succinate) 2.5 mg tablets. CNNMoney.com Need to know - migraine - Apr 11, 2008 Where patients have predictable menstrual migraine attacks, short-term prevention with naratriptan or frovatriptan may prove effective when given for about Pulse, Endo Pharma Withdraws Frova Application From FDA; To Return Rights ... - Apr 7, 2008 ...said it has withdrawn the supplemental new drug application or sNDA without prejudice to refiling for Frova or frovatriptan succinate 2.5 mg tablets. RTT News, UK small caps open lower with wider market; Alphameric dips on ... - Feb 20, 2008 Fundamentally, Landsbanki had historically expected the stock to be worth around 42 pence a share -- excluding frovatriptan in menstrually related migraine, CNNMoney.com Vernalis consolidates in Cambridge following major restructuring - Feb 21, 2008 Vernalis revenues arising from sales of frovatriptan in Europe and elsewhere are unaffected by the settlement. European sales of frovatriptan in 2007 Business Weekly, Recordati in licensing agreement to sell migraine drug in France ... - Feb 14, 2008 Frovatriptan, used for the acute treatment of migraine attacks, is already approved in a series of licensed markets and is sold in those countries by Hemscott, RECORDATI: 2007 ACCOUNTS APPROVED BY THE BOARD. DIVIDEND PER SHARE ... - Mar 9, 2008 ...the leading Italian pharmaceutical group, for the marketing and sales of frovatriptan, a medicine belonging to the triptan group of drugs indicated for PR-USA.net (press release), Vernalis cuts jobs and settles loan as Frova woes start to bite - Feb 20, 2008 Last October, the US Food and Drug Administration turned down a supplemental New Drug Application for Frova (frovatriptan) as a treatment for menstrual Pharma Times (subscription), Vernalis: revised R&D focus after Frova decision hits home - Feb 22, 2008 By Martin Adams In September 2007, the FDA turned down a supplemental New Drug Application (sNDA) for Frova (frovatriptan) for the treatment of menstrual Pharmaceutical Business Review Unique Migraine Treatment Now Available in Canada - Jan 21, 2008 ...(2) Frovatriptan is approved in the US (marketed as FROVA(R)) and across Europe for the acute treatment of migraine and, with a half-life of 26 hours, Canada NewsWire (press release), Ark Pushes Back Vitor To Collect Endpoint Data - Oct 30, 2007 Ark's caution is inspired in part by the fda's recent rejection of Vernalis plc's Frovatriptan in the treatment of menstrual migraine. BioWorld Online, Going abroad? Stock up on right medicines - Nov 14, 2007 Allegro is meant for headache and the active ingredient is Frovatriptan. Increased travel makes it imperative for pharma companies and regulators to sit Hindustan Times, Menstrual Migraine (MM) Represents an Unknown, Yet Potentially ... - Oct 23, 2007 Endo and Vernaliss Frova (frovatriptan) awaits the fdas decision on its application for the short-term prevention of MM. This outcome will be crucial to the Business Wire (press release), Tate & Lyle shares recover some losses - Oct 1, 2007 ..."Frovatriptan is a major driver in our valuation (41.4p of our 88p SOTP valuation), [so] we are downgrading our recommendation from buy to hold, Guardian Unlimited, Vernalis' share value halved by FDA rejection - Oct 2, 2007 He was quick to point out that the action didn't affect the current approved use of Frovatriptan and that Vernalis also has another product on the market in Business Weekly, Vernalis shares slide 50% as FDA rejects sNDA for Frova - Oct 1, 2007 He added that it is important to note that this action does not affect the current approved acute migraine use of frovatriptan and that, in addition to Pharma Times (subscription), Endo Pharmaceuticals and Vernalis Receive Action Letter From FDA ... - Sep 30, 2007 ..."It is important to note that this action does not affect the current approved acute use of Frovatriptan and that, in addition to Frovatriptan, Vernalis has CNNMoney.com Vernalis shares plunge on FDA rejection - Oct 2, 2007 Endo's supplemental new drug application (sNDA) for Frova (frovatriptan succinate) 2.5mg tablets in a "not approvable" letter, according to the company. Pharmaceutical Business Review Frova Rejection By FDA Leaves Partners Annoyed - Oct 2, 2007 Pharmaceuticals Inc. a not approvable letter for the supplemental new drug application for Frova (frovatriptan) in the treatment of menstrual migraine, Therapeutics Daily (subscription) (press release), Endo, Vernalis Receive Action Letter From the FDA - Oct 2, 2007 The sNDA is for the additional indication of Frova (frovatriptan succinate) for the short-term prevention of menstrual migraine. FDA news (subscription), Vernalis cash is running low - Sep 17, 2007 The sales of its two biggest drugs - Frovatriptan for migraine and Apokyn for Parkinson's disease - rose 23% to £1.6m and 35% to £1.9m respectively. Hemscott, Endo, Vernalis set back on new migraine-drug use - Sep 30, 2007 Frova, generically frovatriptan succinate, is approved and marketed to treat migraines "with or without aura in adults where a clear diagnosis of migraine MarketWatch FDA says ‘no’ to Endo drug for menstrual migraines - Oct 1, 2007 Frova, also known by the chemical name frovatriptan succinate, had been widely expected to be approved. "This came as a surprise, as most of the Street had Philadelphia Inquirer, Commercial Insight: Migraine - Opportunities will exist in the ... - Sep 24, 2007 Endo and Vernalis's Frova (frovatriptan) awaits the FDA's decision on its application for the short-term prevention of MM. This outcome will be crucial to Pharmaceutical Business Review Migraines — options to prevent and treat the pounding pain - 07 Sep 2007 Frovatriptan may prevent puncture-related headache -- NEW YORK (Reuters Health) - Frovatriptan, used to prevent and treat migraine headaches, may also be of SpiritIndia, Frovatriptan may prevent puncture-related headache - Aug 24, 2007 NEW YORK (Reuters Health) - Frovatriptan, used to prevent and treat migraine headaches, may also be of use in preventing post-dural puncture headache, Reuters.uk, Good sleep habits could cut intensity of migraines - Sep 5, 2007 Frovatriptan may prevent puncture-related headache -- NEW YORK (Reuters Health) - Frovatriptan, used to prevent and treat migraine headaches, may also be of SpiritIndia, Frovatriptan may prevent headache after lumbar puncture - Aug 24, 2007 NEW YORK (Reuters Health) - Frovatriptan, used in the treatment and prophylaxis of migraine headache, may also be of use in preventing post-dural puncture Therapeutics Daily (subscription) (press release), UK small caps close higher, mirroring wider market; World Trade ... - Aug 17, 2007 Vernalis shares were also on the back foot, dipping 2 to 47-1/2 following news the FDA review of the company's migraine therapy, Frovatriptan, Forbes, UK smallcap opening - Vernalis dips on FDA delay on Frova review - Aug 17, 2007 ...following news that the FDA review of the company's migraine therapy Frovatriptan will not be completed by the planned review date of Aug 19 2007. Forbes, Vernalis shares slip as FDA delays Frova sNDA review again - Aug 17, 2007 New Drug Application for Frova (frovatriptan) 2.5mg tablets for the additional indication as short-term (six days) prevention of menstrual migraine. Pharma Times (subscription), UK small cap lower midday; wider market mixed; Worthington ... - Aug 17, 2007 Vernalis shares, too, were on the back foot, dipping 3-3/4 to 46-1/4 following news that the FDA review of the company's migraine therapy Frovatriptan will Forbes, Endo and Vernalis Provide Update on Frova(R) - Aug 16, 2007 2007 review date in order to have more time to review the supplemental New Drug Application for FROVA® (frovatriptan succinate) 2.5 mg tablets for the CNNMoney.com Players Still Trying To Widen Market For Migraine Therapy - Aug 17, 2007 Endo Pharmaceuticals Inc.'s Frova (frovatriptan) might be able to make headway. But it's too early to put a lot of money on that bet. BioWorld Online, Going the Distance - Aug 16, 2007 Frovatriptan succinate (Frova) is a new triptan medication for menstrual migraine. It is not an appropriate treatment for tension or cluster headaches. ADVANCE for Physician Assistants, Endo Pharma Says FROVA Phase III Study Data Reveals Short-Term ... - Jun 11, 2007 Trading Markets,...double-blind, placebo-controlled clinical trial evaluating FROVA, frovatriptan succinate, 2.5 mg tablets as a six-day preventative treatment in women Endo Pharma Presents Results From Frova Phase III Study For ... - Jun 10, 2007 RTT News,...evaluating Frova, frovatriptan succinate, 2.5 mg tablets as a 6-day preventative treatment in women with difficult-to-treat menstrual migraine, or MM. Migraines inextricably linked with menstruation - Apr 20, 2007 Hindustan Times,Another research led by Stephen D. Silberstein of Thomas Jefferson University in Philadelphia, studied the use of frovatriptan as it has a long therapeutic Vernalis plc Announces Pricing and Reimbursement for Frova® in France - Apr 2, 2007 Oxfordshire Bioscience Network (press release),Frova® (frovatriptan succinate tablets) is a selective 5-HT 1B/1D receptor agonist approved as an acute oral treatment for migraine headache and its Endo and Vernalis Plc Announce Three-Month Extension of PDUFA Date ... - Apr 2, 2007 Oxfordshire Bioscience Network (press release),Application (sNDA) for Frova® (frovatriptan succinate) 2.5 mg tablets for the expanded indication of short-term prevention of menstrual migraine (MM). Triptan-Experienced Migraine Patients Find Improved Management ... Oct 11, 2006 ...migraines and have used medications in the triptan class experience better effectiveness and tolerability when they switch to frovatriptan (Frova), according ... -DG News Vernalis Plc: Interim Results for the Six Months Ended 30 June ... Sep 11, 2006 Parkinson's disease drug, Apokyn(R) (apomorphine hydrochloride injection), as well as co-promoting its migraine drug, Frova(R) (frovatriptan succinate) 2.5 mg ... -PR Newswire Vernalis Plc Announces FDA Acceptance For Filing Of Frova(R) For ... Sep 21, 2006 ...that the US Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Frova(R) (frovatriptan succinate) 2.5 ... -Medical News Today Vernalis plc: Interim Results for the six months ended 30 June ... Sep 13, 2006 ...s Parkinson’s disease drug, Apokyn® (apomorphine hydrochloride injection), as well as co-promoting its migraine drug, Frova® (frovatriptan succinate) 2.5 ... -Oxfordshire Bioscience Network Prevention Strategies Reviewed for Women With Migraines Sep 6, 2006 Miniprophylaxis for menstrual migraine may involve use of naproxen sodium, magnesium, ergotamine tartrate plus caffeine, frovatriptan, naritriptan, or ... -Medscape (subscription) Vernalis plc and Endo Pharmaceuticals Holdings Inc. Announce North ... Aug 7, 2006 Endo�), today announced an agreement for Vernalis to license exclusive North American sales and marketing rights to Frova™ (frovatriptan succinate, 2.5mg ... -Biotechnology Investment Today Systematic approach needed in managing chronic headaches Aug 1, 2006 The triptans, such as sumatriptan nasal spray, zolmitriptan nasal spray and oral frovatriptan, although not yet sanctioned by the Food and Drug Administration ... -AAP News (subscription) FDA Warns on Mixing Antidepressants with Migraine Drugs Jul 20, 2006 Triptans were Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan) Maxalt and Maxalt-MLT (rizatriptan), Relpax (eletriptan ... -Psychiatric Times Endo Pharmaceuticals and Vernalis plc Announce the Filing of the ... Jul 19, 2006 ...that Endo has submitted to the US Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Frova® (frovatriptan succinate) 2.5 mg ... -Yahoo! News Vernalis Submits New Drug Application For Frova >VNLS Jul 20, 2006 ...that Endo has submitted to the US Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Frova (frovatriptan succinate) 2.5 mg ... -Therapeutics Daily (subscription) Vernalis plc to Ring the NASDAQ Closing Bell on May 18, 2006 16 May 2006 ...trading on NASDAQ in July 1992, is celebrating the positive outcome of the Company's second Phase III efficacy study of Frova(R) (frovatriptan succinate) 2.5 ... - PR Newswire Vernalis/Endo: gain in menstrual migraine May 8, 2006 In the study, patients were randomized to receive either placebo or Frova (frovatriptan) for six days in each of three menstrual cycles. ... - Pharmaceutical Business Review Frova(R) Meets Primary Endpoint In Second Phase III Study For ... May 10, 2006 ...(Nasdaq: ENDP) today announced top-line data from the second Phase III efficacy study of Frova(R) (frovatriptan succinate) 2.5 mg tablets for the short-term ... - Medical News Today Vernalis Gets Top-Line Data From Frova Phase III Study May 8, 2006 Monday announced top-line data from the second Phase III efficacy study of Frova (frovatriptan succinate) 2.5 mg tablets for the short-term (six-days per month ... - Therapeutics Daily (subscription) Antisoma appoints Dr Gary Acton as Chief Medical Officer Apr 23, 2006 He was responsible for development of the Company's entire portfolio, including the US and European approvals of frovatriptan, a drug now marketed in all major ... - Market Wire Brand Names/Synonyms: Frovatriptan is also known by the following brand names and/or synonymsFrova; Frovatriptan; Miguard Drug Category: Frovatriptan is categorized under the following by the FDA: Anti-migraine Agents; Vasoconstrictor Agents; Anti-inflammatory Agents; Dosage Forms: Not Available Absorption: The absolute bioavailability of an oral dose of frovatriptan 2.5 mg in healthy subjects is about 20% in males and 30% in females Interactions: -->Interactions for Frovatriptan: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see CONTRAINDICATIONS). Concomitant use of other 5-HT1B/1D agonists within 24 hours of FROVA treatment is not recommended. Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists. If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised. Drug/Laboratory Test Interactions FROVA is not known to interfere with commonly employed clinical laboratory tests. Chemical IUPAC Name: 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |